Gettinger S, Horn L, Jackman D et al (2018) Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the Ca209-003 study. J Clin Oncol 36(17):1675–1684. https://doi.org/10.1200/jco.2017.77.0412

Article  PubMed  Google Scholar 

Knight A, Karapetyan L, Kirkwood JM (2023) Immunotherapy in melanoma: Recent advances and future directions. Cancers (Basel) 15(4):1106. https://doi.org/10.3390/cancers15041106

Article  PubMed  Google Scholar 

Blumenthal GM, Zhang L, Zhang H et al (2017) Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis. JAMA Oncol 3(8):e171029. https://doi.org/10.1001/jamaoncol.2017.1029

Article  PubMed  PubMed Central  Google Scholar 

Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to Pd-1 inhibition. N Engl J Med 377(25):2500–2501. https://doi.org/10.1056/NEJMc1713444

Article  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for Pd-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774

Article  PubMed  Google Scholar 

VanderWalde A, Bellasea SL, Kendra KL et al (2023) Ipilimumab with or without Nivolumab in Pd-1 or Pd-L1 blockade refractory metastatic melanoma: A randomized phase 2 trial. Nat Med 29(9):2278–2285. https://doi.org/10.1038/s41591-023-02498-y

Article  PubMed  PubMed Central  Google Scholar 

Moeckel C, Bakhl K, Georgakopoulos-Soares I et al (2023) The Efficacy of tumor mutation burden as a biomarker of response to immune checkpoint inhibitors. Int J Mol Sci 24(7):6710. https://doi.org/10.3390/ijms24076710

Article  PubMed  PubMed Central  Google Scholar 

Dong ZY, Zhong WZ, Zhang XC et al (2017) Potential Predictive Value of Tp53 and kras mutation status for response to Pd-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23(12):3012–3024. https://doi.org/10.1158/1078-0432.Ccr-16-2554

Article  PubMed  Google Scholar 

Dong Y, Zhao L, Duan J et al (2022) Pappa2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer. Cell Prolif 55(9):e13283. https://doi.org/10.1111/cpr.13283

Article  PubMed  PubMed Central  Google Scholar 

Chudnovsky Y, Kim D, Zheng S et al (2014) Zfhx4 interacts with the nurd Core Member Chd4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep 6(2):313–324. https://doi.org/10.1016/j.celrep.2013.12.032

Article  PubMed  PubMed Central  Google Scholar 

Zong S, Xu PP, Xu YH et al (2022) A bioinformatics analysis: Zfhx4 is associated with metastasis and poor survival in ovarian cancer. J Ovarian Res 15(1):90. https://doi.org/10.1186/s13048-022-01024-x

Article  PubMed  PubMed Central  Google Scholar 

Ha M, Kim J, Park SM et al (2020) Prognostic role of zinc finger homeobox 4 in ovarian serous cystadenocarcinoma. Genet Test Mol Biomarkers 24(3):145–149. https://doi.org/10.1089/gtmb.2019.0185

Article  PubMed  Google Scholar 

Qing T, Zhu S, Suo C et al (2017) Somatic mutations in Zfhx4 gene are associated with poor overall survival of chinese esophageal squamous cell carcinoma patients. Sci Rep 7(1):4951. https://doi.org/10.1038/s41598-017-04221-7

Article  PubMed  PubMed Central  Google Scholar 

Hellmann MD, Nathanson T, Rizvi H et al (2018) Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33(5):843-852.e844. https://doi.org/10.1016/j.ccell.2018.03.018

Article  PubMed  PubMed Central  Google Scholar 

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to Pd-1 blockade in non-small cell lung cancer. Science 348(6230):124–128. https://doi.org/10.1126/science.aaa1348

Article  PubMed  PubMed Central  Google Scholar 

Miao D, Margolis CA, Vokes NI et al (2018) Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 50(9):1271–1281. https://doi.org/10.1038/s41588-018-0200-2

Article  PubMed  PubMed Central  Google Scholar 

Hoadley KA, Yau C, Hinoue T et al (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173(2):291-304.e296. https://doi.org/10.1016/j.cell.2018.03.022

Article  PubMed  PubMed Central  Google Scholar 

Charoentong P, Finotello F, Angelova M et al (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248–262. https://doi.org/10.1016/j.celrep.2016.12.019

Article  PubMed  Google Scholar 

Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48(4):812-830.e814. https://doi.org/10.1016/j.immuni.2018.03.023

Article  PubMed  PubMed Central  Google Scholar 

Roh W, Chen PL, Reuben A et al (2017) Integrated Molecular Analysis of Tumor Biopsies on Sequential Ctla-4 and Pd-1 Blockade Reveals Markers of Response and Resistance. Sci Transl Med 9(379):eaah3560. https://doi.org/10.1126/scitranslmed.aah3560

Article  PubMed  PubMed Central  Google Scholar 

Riaz N, Havel JJ, Makarov V et al (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171(4):934-949.e916. https://doi.org/10.1016/j.cell.2017.09.028

Article  PubMed  PubMed Central  Google Scholar 

Liu D, Schilling B, Liu D et al (2019) Integrative molecular and clinical modeling of clinical outcomes to pd1 blockade in patients with metastatic melanoma. Nat Med 25(12):1916–1927. https://doi.org/10.1038/s41591-019-0654-5

Article  PubMed  PubMed Central  Google Scholar 

Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma. Cell 165(1):35–44. https://doi.org/10.1016/j.cell.2016.02.065

Article  PubMed  PubMed Central  Google Scholar 

Miao W, Li L, Wang Y (2018) A targeted proteomic approach for heat shock proteins reveals dnajb4 as a suppressor for melanoma metastasis. Anal Chem 90(11):6835–6842. https://doi.org/10.1021/acs.analchem.8b00986

Article  PubMed  PubMed Central  Google Scholar 

Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to ctla-4 blockade in metastatic melanoma. Science 350(6257):207–211. https://doi.org/10.1126/science.aad0095

Article  PubMed  PubMed Central  Google Scholar 

Samstein RM, Lee CH, Shoushtari AN et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51(2):202–206. https://doi.org/10.1038/s41588-018-0312-8

Article  PubMed  PubMed Central  Google Scholar 

Goldman MJ, Craft B, Hastie M et al (2020) Visualizing and interpreting cancer genomics data via the xena platform. Nat Biotechnol 38(6):675–678. https://doi.org/10.1038/s41587-020-0546-8

Article  PubMed  PubMed Central  Google Scholar 

Lv C, Fang W, Wu N et al (2023) Osimertinib as neoadjuvant therapy in patients with egfr-mutant resectable stage Ii-Iiib lung adenocarcinoma (Neos): A multicenter, single-arm, open-label phase 2b trial. Lung Cancer 178:151–156. https://doi.org/10.1016/j.lungcan.2023.02.011

Article  PubMed  Google Scholar 

Ren Z, Wang L, Leng C (2023) Ptprd mutation is a prognostic biomarker for sensitivity to icis treatment in advanced non-small cell lung cancer. Aging 15(16):8204–8219. https://doi.org/10.18632/aging.204964

Article